DMD #638
4 Trichostatin A and its glucopyranosyl derivative trichostatin C are hydroxamic acids that were first isolated from cultures of Streptomyces hygroscopicus as antifungal antibiotics active against Trichophyton sp. (Tsuji et al., 1976; Tsuji and Kobayashi, 1978) . Trichostatin A was subsequently found to exhibit potent cytostatic and differentiating activity at nanomolar concentrations against Friend murine erythroleukemia cells in culture (Yoshida et al., 1987) .
Later work identified similar antiproliferative activity against a broad range of human tumorderived cell lines (reviewed in . Stereoselective synthesis of the enantiomers of trichostatin A and subsequent analysis showed that the natural configuration is R-(+)-trichostatin A and S-(-)-trichostatin A is 70 times less biologically active (Yoshida et al., 1990a) . Nuclear histones from cells treated with trichostatin A were found to be highly acetylated and on pulse-chase analysis this was due to decreased deacetylation rather than increased acetylation (Yoshida et al., 1990b) . This observation led to the subsequent identification of histone deacetylase as the specific molecular target of trichostatin A (Yoshida et al., 1990b) .
The equilibrium between the opposing activities of histone acetyltransferase and histone deacetylase enzymes determines global cellular acetylation status (Struhl, 1998; Kouzarides, 1999) . Reversible post-translational acetylation of ε-amino groups of highly conserved lysine residues in nucleosome core histones is important in the modification of chromatin superstructure and accessibility of the transcriptional apparatus to promoters of target genes (Pazin and Kadonaga, 1997; Wade et al., 1997; Wolffe, 1997) . Histone deacetylase inhibition is in general associated with transcriptional activation of certain genes, e.g. CDKN1A (the gene for p21), but also repression of others, e.g. CCND1 which encodes cyclin D1 (Krajewski, 1999; Cress and Seto, 2000; Magnaghi-Jaulin et al., 2000) . In addition to histones, other cellular proteins are also modified by acetylation including transcription factors, e.g. p53 and E2F, nuclear hormone receptors, e.g. estrogen receptor α, and α -tubulin (reviewed in . Acetylation, therefore, is involved in many diverse cellular processes.
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Trichostatin A is a potent, specific and reversible histone deacetylase inhibitor at low nanomolar concentrations (Yoshida et al., 1990b) . The biological consequences of histone deacetylase inhibition include reversion of transformed cell morphology and inhibition of cell proliferation by induction of G 1 /S and G 2 /M phase cell cycle arrest, differentiation and/or apoptosis (reviewed in . Trichostatin A has potent broad spectrum antitumor activity against virtually all transformed cell types in culture including cell lines derived from epithelial and hematological malignancies (Li et al., 1996; Lin et al., 1998; Kosugi et al., 1999; Saunders et al., 1999; Marks et al., 2000) . We previously observed that trichostatin A had potent antitumor activity without apparent toxicity in vivo in the N-methyl-Nnitrosourea (NMU) carcinogen-induced rat mammary cancer model (Vigushin et al., 2001 ).
Trichostatin A also exhibits antitumor efficacy in the murine Lewis lung carcinoma model (Kim et al., 2001) . Furthermore, trichostatin A is therapeutically active at non-toxic doses in various murine models of nonmalignant human disease including cardiomyocyte hypertrophy (Kook et al., 2003) , premature parturition (Condon et al., 2003) , glomerulonephritis in systemic lupus erythematosus (Mishra et al., 2003) , and hepatic fibrosis induced by carbon tetrachloride (Elaut et al., 2002) .
The biotransformation of trichostatin A in vitro has previously been reported (Elaut et al., 2002) . Trichostatin A was rapidly and completely metabolized by rat hepatocytes; the major phase I biotransformation pathways were identified as N-demethylation and reductive amination of the hydroxamic acid; hydrolysis of trichostatin A to trichostatic acid was a minor pathway. In contrast, trichostatin A was slowly and incompletely metabolized by Ndemethylation in rat and human microsome preparations, suggesting that trichostatin A reduction was catalyzed by nonmicrosomal enzymes. An intact hydroxamic acid function suggested that the N-demethylated trichostatin A metabolites may be pharmacologically active. Here we report on the in vivo plasma pharmacokinetics of trichostatin A and characterization of its plasma metabolites after single dose intraperitoneal administration to female Balb/C mice. 
Materials and Methods
Chemicals and Reagents
Trichostatin A (7-[4-(dimethylamino)phenyl]-4,6-dimethyl-7-oxo-hepta-2,4-dienoic acid hydroxamide; ≥ 99% purity) was from Wako Chemicals GmbH (Neuss, Germany). HPLC (far UV) grade acetonitrile and Aristar grade formic acid were purchased from VWR International (Dorset, United Kingdom). All other reagents were from Sigma-Aldrich Ltd (Dorset, United Kingdom).
Animals and Procedures
Female Balb/C mice (15-25 g) and female Ludwig Wistar rats (100-200 g) from Harlan Ltd.
(Oxfordshire, United Kingdom) were maintained in accordance with the Animals (Scientific Procedures) Act, 1986. Animals were kept in controlled conditions of light, temperature and humidity, and fed a standard diet with water ad libitum. Individual animals were weighed and dosed by intraperitoneal injection of trichostatin A 80 mg/kg (mice) or 0.5 mg/kg (mice or rats) in 60 µl 10% (v/v) dimethyl sulfoxide in filtered peanut oil. Syringes were flushed with an aqueous solution of bovine heparin (5000 U/ml). Animals were anesthetized with isoflurane at 2, 3.5, 5, 10, 15, 20, 30, 60 min, 24 , or 48 h post-injection and blood was collected by cardiac puncture into heparin-flushed syringes. Plasma was separated immediately by centrifugation (4750g for 5 min at room temperature) and samples were stored at -70°C until analyzed.
HPLC-UV measurement of trichostatin A in plasma
HPLC analysis was carried out using a Jasco (Essex, United Kingdom) PS1585 HPLC system with MD1510 diode array detector. Plasma aliquots (100 µl) were thawed and each treated with 200 µl acetonitrile. Samples were centrifuged at 4750g for 10 min at room temperature and the supernatants were collected and then dried by rotary vacuum evaporation (without heating).
Each sample was reconstituted in 150 µl 
HPLC-multiple reaction monitoring assay
Trichostatin A was also measured by HPLC-multiple reaction monitoring (MRM) using a Jasco modular HPLC system coupled to a Micromass Quattro II triple quadrupole mass 
Identification of metabolites
The remaining 20-min plasma samples from the high dose study were combined and prepared for HPLC-diode array UV analysis. The HPLC eluant (split 1/13) was directed to a Quattro II triple quadrupole mass spectrometer for analysis by positive ion electrospray-MS mode. The ion source was operated at 75°C with a cone potential of 24V. Scans (1 s/scan) were obtained between m/z 200-400. The remaining eluant was collected in 1 min fractions.
Ten µl of each fraction was injected directly onto the mass spectrometer for product ion analysis by positive ion electrospray-MS-MS. The collision gas was argon at a pressure of 2.1 x 10 -3 mbar and the collision energy was set to 24eV. The fractions were also analyzed on a Thermo LCQ Deca Ion Trap mass spectrometer (Thermo Electron Corporation;
Waltham, MA) in the MS n mode. The remaining fractions were dried under vacuum and each resuspended in 50 µl dimethyl sulfoxide for determination of histone deacetylase inhibitory activity as previously described (Vigushin et al., 2001; Marson et al., 2004) with the modifications detailed below.
Histone deacetylase assay
The assay was performed in a final reaction volume of 200 µl. µg trichostatin A (r 2 >0.999), with the limit of detection set at 10 ng and limit of quantification set at 50 ng. The assay was reproducible with intra-assay and inter-assay coefficients of variation of 12.5% (n=5) and 18.5% (n=10), respectively. Analytical precision was 89%.
HPLC-UV analysis of mouse plasma following intraperitoneal administration of trichostatin A
showed the presence of a number of A 351 absorbing components; seventeen UV absorbing peaks were detected in the 20 min post injection sample, (Fig. 1A) . Trichostatin A (peak 8) was well separated from these components and was identified, and adjudged to be a single The HPLC-UV assay was insufficiently sensitive to monitor trichostatin A levels following low dose administration and so an HPLC-multiple reaction monitoring (MRM) assay was
developed. An internal standard was prepared by methylating commercially available 4-dimethylamino-N-(6-hydroxycarbamoylhexyl)benzamide to form the monomethyl derivative.
Using modified HPLC conditions (system 2), trichostatin A eluted at 13.3 min, and the internal standard at 14.7 min. The internal standard generated an intense protonated molecular ion (M+H + ) at m/z 336 and fragmented by collision-induced dissociation to form the dimethylamino-phenylcarbonyl ion (m/z 148); this ion is also generated by collisioninduced dissociation of the M+H + (m/z 303) ion of trichostatin A. These ion transitions (336→148 and 303→148) were then used as the basis for MRM assay. Using the HPLC-MRM assay there was no evidence for trichostatin A in blank plasma. The assay had a limit of detection of 0.2 ng, limit of quantification of 0.4 ng, analytical precision of 96%, and intraassay and inter-assay coefficients of variation of 10.6% and 12%, respectively. The assay was linear from 0.5 ng to 100 ng on column (r 2 >0.998). In each case the internal standard was recovered in similar yield.
Using the assay, mouse plasma was analyzed at various times after administration of low dose (0.5 mg/kg) trichostatin A. The data are shown in figure 2B ; trichostatin A rapidly appears in plasma by 2 min (C max 8 ng/ml), and decays exponentially between 5 and 60 min with a t 1/2 of 9.6 min. There was no evidence of trichostatin A in plasma samples taken at 24
h and 48 h. These pharmacokinetics are similar to those obtained with the high dose study.
Two rats were also treated with low dose (0.5 mg/kg) trichostatin A. Although plasma trichostatin A was detected at 2 min, the maximum concentration reached was only 3.5 ng/ml. Trichostatin A had been completely eliminated by 24 h.
The 20-min plasma sample from the high dose mouse study was selected for further examination of the other A 351 components and their UV spectra and ESP mass spectra were scrutinized (Fig. 1B, Table 1 ). The UV spectra were similar to that of trichostatin A, with (7, 8, 10b, 10c, 12, 13, 15, 16) . A second group of metabolites (3, 5, 6, 10a, 11) generated a fragment at m/z 134 characteristic of an N-methylaminophenylcarbonyl group arising through N-demethylation. Metabolites 4 and 9 generated characteristic fragments at m/z 174 and 188. The molecular weight and fragmentation data (Table 1) ((CH 3 ) 2 N=C 6 H 6 + ). This is consistent with an N-O methylated trichostatin A. There was no conclusive evidence for either didemethylation or ring oxidation to produce aminophenyl or phenolic metabolites. Some minor components were observed with molecular weights consistent with didemethylation, but insufficient material was available for confirmatory MS-MS analysis.
Since the absorption coefficients of the identified metabolites were unknown and standards were not available, it was not possible to determine the absolute concentrations of the metabolites in plasma at the various time points. However, if it is assumed that the absorption coefficients do not differ significantly from that of trichostatin A, the peak areas can be used to estimate their concentration comparative to that of trichostatin A. The trichostatin A equivalent concentrations of metabolites that were completely resolved by the HPLC assay are shown in Figure 4 . N-demethyl trichostatin A amide was the major metabolite produced, reaching a concentration of approximately 20 µg/ml (trichostatin A equivalents) after 60 min. It is unclear how long this compound persisted in the plasma because samples were not collected beyond this time point. Dihydro trichostatic acid and dinor dihydro trichostatic acid both reached a significant plasma concentration of approximately 13 µg/ml after 10 to 15 min, however these compounds then declined rapidly.
The 20-min post-injection plasma sample was separated by HPLC into 1-min fractions. Each fraction was then tested for histone deacetylase inhibitory activity in vitro (Fig. 1C ). There were two main areas of activity, comprising fractions 20/21 and 24/25. Each of these fractions showed 92-99% inhibition of histone deacetylase enzyme activity, a level of activity comparable to that of 100 nM (approx 30 ng/ml) trichostatin A (results not shown). HPLC-MS-MS analysis of these fractions showed that the earlier eluting activity was associated with N-demethyl trichostatin A, with trichostatin A accounting for the later eluting activity.
Other metabolites were also present in these fractions.
Discussion
Following intraperitoneal administration of trichostatin A in mice at two different doses, unchanged trichostatin A appeared in the circulation within 2 min, and was then rapidly cleared with first order kinetics for the high (80 mg/kg) and low (0.5 mg/kg) doses, respectively. Plasma pharmacokinetics was similar for both doses suggesting that the metabolism and clearance are not materially affected by dosage. Plasma trichostatin A levels following high dose administration remained above 200 ng/ml for up to 60 min and this is well above the minimum required (0.5 ng/ml) to inhibit histone deacetylase activity in vitro (Vigushin et al., 2001) . In contrast, low dose trichostatin A was only just present at bioactive concentrations at 60 min, and was completely eliminated by 24 h. The bioactive dose of trichostatin A in the NMU-induced rat mammary cancer model is at least 40-fold lower than in human breast cancer xenograft models in mice (Vigushin, unpublished observation) . This is probably not due to pharmacokinetic reasons: following low dose (0.5 mg/kg) intraperitoneal administration in 2 rats trichostatin A appeared in plasma, but at only slightly lower levels than in the mouse (C max 3.5 ng/ml), and was eliminated by 24 h. Of the metabolites identified in the present study only N-demethyl trichostatin A had potent histone deacetylase inhibitory activity in vitro. Other than trichostatin A this was the only structure with an intact hydroxamic acid group, supporting the hypothesis that chelation of zinc at the base of the histone deacetylase enzyme active site by the hydroxamic acid group of trichostatin A, prevents binding of the natural acetyl lysine substrate (Finnin et al., 1999) .
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